The University of Southampton
University of Southampton Institutional Repository

Tyrosine kinase fusion genes in chronic myeloproliferative diseases

Tyrosine kinase fusion genes in chronic myeloproliferative diseases
Tyrosine kinase fusion genes in chronic myeloproliferative diseases
With the exception of chronic myeloid leukemia (CML), chronic myeloproliferative disorders (CMPDs) are a heterogeneous spectrum of conditions for which the molecular pathogenesis is not well understood. Most cases have a normal or aneuploid karyotype, but a minority present with a reciprocal translocation that disrupts specific tyrosine kinase genes, most commonly PDGFRB or FGFR1. These translocations result in the production of constitutively active tyrosine kinase fusion proteins that deregulate hemopoiesis in a manner analogous to BCR-ABL. With the advent of targeted signal transduction therapy, an accurate clinical and molecular diagnosis of CMPDs has become increasingly important. Currently, patients with PDGFRB or ABL fusion genes are candidates for treatment with Imatinib (STI571), but it is likely that alternative strategies will be necessary for the treatment of most other patients.
tyrosine kinase, myeloproliferative disorders, ABL, FGFR1, PDGFRB, JAK2
0887-6924
1207-1212
Cross, N.C.P.
f87650da-b908-4a34-b31b-d62c5f186fe4
Reiter, A.
8fc082eb-6b46-4412-86b2-f4c7669f0650
Cross, N.C.P.
f87650da-b908-4a34-b31b-d62c5f186fe4
Reiter, A.
8fc082eb-6b46-4412-86b2-f4c7669f0650

Cross, N.C.P. and Reiter, A. (2002) Tyrosine kinase fusion genes in chronic myeloproliferative diseases. Leukemia, 16 (7), 1207-1212. (doi:10.1038/sj.leu.2402556).

Record type: Article

Abstract

With the exception of chronic myeloid leukemia (CML), chronic myeloproliferative disorders (CMPDs) are a heterogeneous spectrum of conditions for which the molecular pathogenesis is not well understood. Most cases have a normal or aneuploid karyotype, but a minority present with a reciprocal translocation that disrupts specific tyrosine kinase genes, most commonly PDGFRB or FGFR1. These translocations result in the production of constitutively active tyrosine kinase fusion proteins that deregulate hemopoiesis in a manner analogous to BCR-ABL. With the advent of targeted signal transduction therapy, an accurate clinical and molecular diagnosis of CMPDs has become increasingly important. Currently, patients with PDGFRB or ABL fusion genes are candidates for treatment with Imatinib (STI571), but it is likely that alternative strategies will be necessary for the treatment of most other patients.

Full text not available from this repository.

More information

Published date: 2002
Keywords: tyrosine kinase, myeloproliferative disorders, ABL, FGFR1, PDGFRB, JAK2

Identifiers

Local EPrints ID: 24669
URI: http://eprints.soton.ac.uk/id/eprint/24669
ISSN: 0887-6924
PURE UUID: b50e27b9-ba18-470f-a9a5-012784677e5e
ORCID for N.C.P. Cross: ORCID iD orcid.org/0000-0001-5481-2555

Catalogue record

Date deposited: 03 Apr 2006
Last modified: 17 Dec 2019 01:51

Export record

Altmetrics

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×